Typhoid Fever Clinical Trial
Official title:
Evaluation of DPP® Typhoid Assay (Chembio Diagnostic System, Inc) for the Diagnosis of Typhoid From Well Characterized Serum Sample.
NCT number | NCT05579821 |
Other study ID # | FE006C |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 15, 2022 |
Est. completion date | June 30, 2023 |
Verified date | November 2023 |
Source | Foundation for Innovative New Diagnostics, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Fever management is a major problem in Low and Middle Income Countries (LMICs) where access to good quality diagnostic test is often unavailable. Fever due to typhoid is similar to other undifferentiated febrile illnesses and typhoid can be mistaken with other vector borne febrile illnesses such as scrub typhus. Currently available diagnostic tests, blood and bone marrow culture, and RDTs have several limitations including a low sensitivity and specificity . Recently, several antigens of Salmonella Typhi useful for serodiagnosis of typhoid has been identified. Salmonella Typhi lipopolysaccharide (LPS) and hemolysin E (HlyE) have been identified as top candidate antigens by several studies to differentiate acute typhoid patients from healthy individuals. DPP® Typhoid Assay is a multiplex rapid test that detects IgA antibodies to LPS and HlyE antigen. It is considered to have high sensitivity and specificity and its results were found to be highly correlated with ELISA results. However, very few studies have been conducted to evaluate this test and limited information about the accuracy of this test is present. Hence, this study will evaluate the sensitivity and specificity of this test in archived serum sample of well characterized blood culture positives and negatives in support of new innovation on typhoid diagnostics.
Status | Completed |
Enrollment | 387 |
Est. completion date | June 30, 2023 |
Est. primary completion date | November 30, 2022 |
Accepts healthy volunteers | |
Gender | All |
Age group | 2 Years to 65 Years |
Eligibility | Inclusion Criteria: - Inclusion criteria identical to the prior prospective study in AKU (Protocol ref number: FE006) - Serum stored frozen at AKU as a part of afore mentioned study and cold-chain maintained. Exclusion Criteria: - Samples whose reference standard data (Blood culture report) are not available in FIND's OpenClinica database. |
Country | Name | City | State |
---|---|---|---|
Pakistan | Aga Khan University | Karachi |
Lead Sponsor | Collaborator |
---|---|
Foundation for Innovative New Diagnostics, Switzerland | Aga Khan University |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Point estimates of sensitivity and specificity with 95% confidence interval of DPP Typhoid assay using blood culture as reference standard | October 2022 | ||
Secondary | Estimates of operational characteristics of DPP Typhoid Assay, based on quantitative assessment including invalid rates | Nov 2022 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04830371 -
Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
|
Phase 2/Phase 3 | |
Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
Completed |
NCT02324751 -
Vaccines Against Salmonella Typhi
|
Phase 2 | |
Completed |
NCT01421693 -
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
|
Phase 4 | |
Completed |
NCT02947295 -
Global Genomic and Proteomic Profiling of African Children With Typhoid Fever
|
||
Completed |
NCT01405521 -
Understanding Typhoid Disease After Vaccination
|
Phase 2 | |
Completed |
NCT00386789 -
Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age
|
N/A | |
Completed |
NCT04801602 -
Commercial Typhoid Tests Validation Trial
|
||
Recruiting |
NCT06104345 -
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
|
Phase 4 | |
Completed |
NCT01437267 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
|
Phase 2 | |
Completed |
NCT01438996 -
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
|
Phase 2 | |
Completed |
NCT01193907 -
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
|
Phase 2 | |
Recruiting |
NCT04349826 -
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
|
Phase 4 | |
Completed |
NCT01608815 -
Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
|
Phase 3 | |
Completed |
NCT01123941 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
|
Phase 1 | |
Recruiting |
NCT05500482 -
Vellore Typhoid Vaccine Impact Trial
|
Phase 4 | |
Completed |
NCT03926455 -
Safety and Immunogenicity of Typhax, a Typhoid Vaccine
|
Phase 1 | |
Completed |
NCT01229176 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
|
Phase 2 | |
Completed |
NCT03956524 -
Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
|
Phase 1 | |
Completed |
NCT04154722 -
Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children
|
Phase 4 |